37 results on '"Zimran, Eran"'
Search Results
2. Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET).
3. Dysregulated iron metabolism in polycythemia vera: etiology and consequences.
4. Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study
5. Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic
6. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation
7. OA-34 Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis
8. P-026 Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma
9. High rate of adenovirus detection in gastrointestinal biopsies of symptomatic stem cell transplant recipients
10. Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
11. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology [version 1; peer review: 3 approved]
12. Risk factors and outcomes of COVID‐19 in adult patients with hematological malignancies: A single‐center study showing lower than expected rates of hospitalization and mortality.
13. ATG-F Versus ATG-T for Graft Versus Host Disease Prevention in Allogeneic Stem Cell Transplantation: A Retrospective Comparative Study
14. Tecam (Thiotepa, Etoposide, cyclophosphamide, Cytarabine and Melphalan) Is an Effective and Safe Conditioning Regimen for Autologous Transplant in Lymphoma
15. Letermovir Prophylaxis for High-Risk Allogenic Transplantation Recipients, Real- World Israeli Experience
16. Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results
17. Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
18. Mesenchymal stroma/stem cells: Haematologists’ friend or foe?
19. Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma
20. Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients’ outcome
21. COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic
22. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome
23. Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcome.
24. Expansion and preservation of the functional activity of adult hematopoietic stem cells cultured ex vivo with a histone deacetylase inhibitor
25. Novel treatments to tackle myelofibrosis
26. Ex vivo human HSC expansion requires coordination of cellular reprogramming with mitochondrial remodeling and p53 activation
27. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology
28. Genomic characterization of spleens in patients with myelofibrosis
29. Current approaches to challenging scenarios in myeloproliferative neoplasms
30. The Exhaustion of Adult Hematopoietic Stem Cells in Ex Vivo Cultures Can Be Overcome by a Histone Deacetylase Inhibitor
31. Bilateral Adrenal Hemorrhage in a Patient with Antiphospholipid Syndrome Following Reversal of Warfarin-induced Over-anticoagulation.
32. Valproic Acid Expands the Numbers of HSCs from Cord Blood CD34+ Cells By Linking Epigenetic Modifications to Mitochondrial Remodeling and p53 Upregulation
33. The Utility of a Coagulation Laboratory Profile in Addition to Clinical Risk Factors for Thrombosis Risk Evaluation in Patients with Myeloproliferative Neoplasms: A Pilot Study
34. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
35. Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma
36. Valproic Acid Expands the Numbers of HSCs from Cord Blood CD34+Cells By Linking Epigenetic Modifications to Mitochondrial Remodeling and p53 Upregulation
37. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.